Consequently, food companies are rushing to reformulate products for protein lovers. That’s a category that includes both people taking the powerful new class of obesity drugs known as GLP-1s, who are ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company (NYSE ... showed that Zepbound provided 47% greater relative weight loss compared to Wegovy. Lilly has also been able to rectify issues around keeping up with demand much ...

Wegovy is a weekly injectable weight loss treatment ... it may be able to launch as early as next year. Eli Lilly also says its oral pill may be available next year.

Top-line results from the Phase 3b SURMOUNT-5 study showed that Zepbound provided 47% greater relative weight loss compared to Wegovy. Lilly has also been able to rectify issues around keeping up ...

Eli Lilly’s profit doubled in the fourth quarter ... They compete with Ozempic and Wegovy from the Danish drugmaker Novo Nordisk, which also reported strong sales growth on Wednesday.

Wegovy is a weekly injectable weight loss treatment ... it may be able to launch as early as next year. Eli Lilly also says its oral pill may be available next year. When Novo Nordisk files ...